Lecanemab 2.5 mg/kg + Lecanemab 5.0 mg/kg + Lecanemab 10 mg/kg + Lecanemab 5.0 mg/kg + Lecanemab 10 mg/kg + Placebo + Lecanemab 10 mg/kg

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Dec 20, 2012 → Dec 10, 2024

NCT ID

NCT01767311

About Lecanemab 2.5 mg/kg + Lecanemab 5.0 mg/kg + Lecanemab 10 mg/kg + Lecanemab 5.0 mg/kg + Lecanemab 10 mg/kg + Placebo + Lecanemab 10 mg/kg

Lecanemab 2.5 mg/kg + Lecanemab 5.0 mg/kg + Lecanemab 10 mg/kg + Lecanemab 5.0 mg/kg + Lecanemab 10 mg/kg + Placebo + Lecanemab 10 mg/kg is a phase 2 stage product being developed by Eisai for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01767311. Target conditions include Alzheimer's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer's Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01767311	Phase 2	Completed	Dec 20, 2012	Dec 10, 2024	Alzheimer's Disease

Competing Products

20 competing products in Alzheimer's Disease

See all competitors

Product	Company	Stage	Hype Score
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
GSK4527226	Alector	Phase 2	29
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
simufilam	Cassava Sciences	Phase 2	17
Remternetug + Placebo	Eli Lilly	Phase 3	44
solanezumab	Eli Lilly	Phase 2	35
LY2886721 + Placebo	Eli Lilly	Phase 1	29
Gantenerumab + Gantenerumab + Gantenerumab + Placebo	Chugai Pharmaceutical	Phase 1	29
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.	Yuhan	Approved	39
FK962	Astellas Pharma	Phase 2	27
ASP0777 + Placebo	Astellas Pharma	Phase 1	29
Elenbecestat + Placebo	Eisai	Phase 3	32
Donepezil	Eisai	Approved	43
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)	Eisai	Phase 3	40
Donepezil hydrochloride	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Pre-clinical	26